Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany

Annika Herr and Moritz Suppliet

Health, Econometrics and Data Group (HEDG) Working Papers from HEDG, c/o Department of Economics, University of York

Abstract: Co-payments are a common instrument of health insurers to lower their pharmaceutical expenses and to share costs with consumers, the patients. Tiered drug co-payments, e.g. lower co-payments for generic drugs, incentivize patients to buy certain products and, hence, steer drug consumption patterns. Since 2007, the German Statutory Health Insurance follows an innovative and unique regulation by differentiating drug copayments by the drug's price relative to its reference price. Co-payment exemption thresholds have been introduced in 185 out of 281 therapeutic clusters since 2007. We answer how effective this co-payment exemption policy is in order to reduce overall prices for pharmaceutical products. We analyze prices of all drugs marketed in reference price clusters and being subject to the policy in Germany using quarterly data from January 2007 to October 2010 published by the Federal Association of Statutory Health Insurance Funds in Germany. Wend empirical evidence of differentiated price setting strategies by different rm types ranging from price decreases of -8% to increases of +1.3% (innovators) following the introduction of co-payment exemption threshold. We refer to the latter case as the co-payment paradox. Furthermore, prices of generic and branded generic rms and reference prices tend to converge. The results are robust when we estimate static and dynamic linear panel data models and control for the heterogeneity of active ingredient's clusters, autocorrelation, and heteroscedasticity. Our competition proxies (no. of rms and ratio products/rm in the same market) suggest a signicant negative impact of competition on prices and, thereby, question whether more competition may be an alternative way to lower pharmaceutical prices.

Date: 2011-07
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.york.ac.uk/media/economics/documents/herc/wp/11_18.pdf Main text (application/pdf)

Related works:
Working Paper: Cost-Sharing and Drug Pricing Strategies: Introducing Tiered Co-Payments in Reference Price Markets (2016)
Working Paper: Cost-Sharing and Drug Pricing Strategies: Introducing Tiered Co-Payments in Reference Price Markets (2016)
Working Paper: Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany (2012)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:yor:hectdg:11/18

Access Statistics for this paper

More papers in Health, Econometrics and Data Group (HEDG) Working Papers from HEDG, c/o Department of Economics, University of York HEDG/HERC, Department of Economics and Related Studies, University of York, York, YO10 5DD, United Kingdom. Contact information at EDIRC.
Bibliographic data for series maintained by Jane Rawlings (jane.rawlings@york.ac.uk).